Loading
Chemomab Therapeutics Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Jun 2026.
Chemomab Therapeutics Ltd.: what insiders have been doing
Chemomab Therapeutics Ltd. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 2 insiders published 6 filings.
The record shows 2 purchases on the open market worth €17k, made by 1 insider, against 2 sales worth €5,589 by 1 insider. Purchases outweigh sales by €12k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 chief executive. The largest single trade was a purchase of €8,822 by Mor George Adi, published on 1 June 2026, equal to 0.074% of the market capitalisation.
The last insider purchase was made public on 1 June 2026, 139 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 6 filings, this issuer sits below that mark. Our records for Chemomab Therapeutics Ltd. go back to 2021, with 11 purchases and 6 sales on the open market in total.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€60,258
11 ops. · all time
Sell Volume
€2M
6 ops. · all time
Who traded when
BuySaleGeorge Adi Mor2 buys
Neil Harris Cohen2 sales
Since the insiders bought
- -22.4%Entry US$1.74 · Close 16 Oct 2026 US$1.35
- -62.8%Entry US$14.40 · Close at T+365 US$5.36
- -46.0%Entry US$12.00 · Close at T+365 US$6.48
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.29
Analyst consensus
1 analysts2.00/5
US$5.00Target US$5.00(+288%)US$5.00
Income statement
EBITDA-US$9.5M
Net income-US$9M0.0% margin
Valuation
PER (forward)-43.0x
P/Book1.1x
Beta0.74
Balance sheet & cash
Market capUS$9.5M
Free Cash Flow-US$11.1M
Profitability & ownership
ROE-82.2%
ROA-46.3%
% insiders12.2%
% institutions19.1%
Last declaration on 1 September 2026
Declarations19 total
1,304 shares@ US$2.850.023% mcap8.6% of flowAmerican Depositary SharesSEC:0001178913-26-004371:0
1,000 shares@ US$2.800.017% mcap6.5% of flowAmerican Depositary SharesSEC:0001178913-26-004371:1
4,878 shares@ US$2.050.073% mcap1.2% of flowAmerican Depositary SharesSEC:0001178913-26-003004:0
Canonical exit: 27 Aug 2026 (T+90)
4,926 shares@ US$2.080.074% mcap1.2% of flowAmerican Depositary SharesSEC:0001178913-26-003004:1
Canonical exit: 27 Aug 2026 (T+90)
31,712 sharesAmerican Depositary SharesSEC:0001178913-26-003004:2
18,750 sharesAmerican Depositary SharesSEC:0001178913-26-003004:3
266,376 shares@ US$3.34100.0% of flowAmerican Depository SharesSEC:0000947871-23-000015:0
7,700 shares@ US$5.02685.1% of flowAmerican Depositary SharesSEC:0001178913-23-000076:0
2,409 shares@ US$2.0012.5% of flowAmerican Depositary SharesSEC:0001178913-22-004100:0
324,775 shares@ US$2.084892.4% of flowAmerican Depositary SharesSEC:0001178913-22-004098:0
250 shares@ US$3.300.0063% mcap45.1% of flowAmerican Depositary SharesSEC:0001178913-22-002402:0
Canonical exit: 14 Jun 2022 (T+90)
400 shares@ US$2.8935.6% of flowAmerican Depositary SharesSEC:0001178913-22-002173:0
Canonical exit: 22 Aug 2022 (T+90)
2,000 shares@ US$3.1916.4% of flowAmerican Depositary SharesSEC:0001178913-22-002093:0
Canonical exit: 16 Aug 2022 (T+90)
500 shares@ US$4.3264.4% of flowAmerican Depositary SharesSEC:0001178913-22-001181:0
Canonical exit: 16 Jun 2022 (T+90)
250 shares@ US$4.0054.9% of flowAmerican Depositary SharesSEC:0001178913-22-001179:0
Canonical exit: 12 Jun 2022 (T+90)
2,000 shares@ US$4.2020.7% of flowAmerican Depositary SharesSEC:0001178913-22-001117:0
Canonical exit: 12 Jun 2022 (T+90)
1,800 shares@ US$3.98100.0% of flowAmerican Depositary SharesSEC:0001178913-22-001120:0
Canonical exit: 12 Jun 2022 (T+90)
1,200 shares@ US$4.28100.0% of flowAmerican Depositary SharesSEC:0001178913-22-001072:0
Canonical exit: 9 Jun 2022 (T+90)
2,000 shares@ US$7.4335.4% of flowAmerican Depositary SharesSEC:0001178913-21-003807:0
Canonical exit: 6 Mar 2022 (T+90)
19 of 19 declarations
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. (ticker: CMMB) is a clinical-stage biopharmaceutical company listed on the Nasdaq in the United States (United States). For international equity investors, the company is best understood as a specialty biotech focused on fibro-inflammatory diseases — conditions in which chronic inflammation and fibrosis drive progressive organ damage. Chemomab’s strategy is centered on developing differentiated therapies for indications with substantial unmet medical need, then using clinical data and regulatory milestones to create optionality for partnering, licensing, or eventual commercialization. ([investors.chemomab.com](https://investors.chemomab.com/2026-03-19-Chemomab-Therapeutics-Announces-Year-End-and-Fourth-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update?utm_source=openai))
Chemomab’s current corporate identity dates back to its 2021 merger with Anchiano Therapeutics, after which the combined company began trading under the CMMB symbol on the Nasdaq Capital Market. Although the equity trades in the U.S. market, the company’s operational base is in Tel Aviv, Israel, giving it a cross-border profile that is common among development-stage biotechnology issuers seeking access to U.S. capital markets while running research and development outside the United States. ([nasdaq.com](https://www.nasdaq.com/press-release/chemomab-completes-merger-with-anchiano-therapeutics-2021-03-16?utm_source=openai))
Read moreShow less
The company’s pipeline is highly concentrated around nebokitug, a first-in-class dual-activity monoclonal antibody designed to neutralize soluble CCL24, a protein implicated in fibrotic and inflammatory pathways. Chemomab is advancing nebokitug in primary sclerosing cholangitis (PSC) as its lead clinical opportunity, while also evaluating broader utility in other severe fibro-inflammatory diseases, including systemic sclerosis. According to company disclosures, nebokitug has received important regulatory designations, including FDA Fast Track and orphan-drug status in PSC, as well as orphan-drug recognition for systemic sclerosis in the U.S. and Europe. That gives the asset a clearer development pathway than many early-stage biotech programs, although the company remains pre-commercial and therefore highly dependent on clinical execution. ([investors.chemomab.com](https://investors.chemomab.com/2026-05-14-Chemomab-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update?utm_source=openai))
From a competitive standpoint, Chemomab is a small-cap biotech rather than a diversified pharmaceutical platform. Its value proposition rests on target biology, clinical differentiation, and the potential to address diseases with limited treatment options. The company has reported positive results from five nebokitug clinical trials, and management has said that FDA alignment on a Phase 3 registration study in PSC followed the positive Phase 2 SPRING trial. In its March 19, 2026 update, Chemomab said it completed a successful FDA end-of-Phase 2 meeting and reached alignment on a clear and efficient path toward potential approval in PSC. The company also stated in February 2025 that the World Health Organization’s INN program assigned the nonproprietary name nebokitug to its lead candidate CM-101. ([investors.chemomab.com](https://investors.chemomab.com/2026-03-19-Chemomab-Therapeutics-Announces-Year-End-and-Fourth-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update?utm_source=openai))
Geographically, Chemomab is globally structured: R&D and management are anchored in Israel, while financing, disclosure, and investor access are centered on the U.S. Nasdaq market. Recent corporate updates underscore a company that is moving from proof-of-concept toward later-stage clinical planning. For example, management highlighted the completion of the Phase 2 PSC trial, the ongoing advance of strategic partnership discussions, and a cash runway expected into the end of the first quarter of 2027 as of the company’s March 2026 financial update. For investors, CMMB remains a high-risk/high-upside biotech story driven by regulatory catalysts, clinical readouts, and balance-sheet discipline. ([nasdaq.com](https://www.nasdaq.com/press-release/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2025-financial-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
